{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:43Z","timestamp":1794003883978,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104979","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:27:02Z","timestamp":1787034422000},"page":"104979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incremental risk of high-grade adverse events with immune checkpoint inhibitors with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in first-line treatment of advanced endometrial cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Mariana Carvalho","family":"Gouveia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0217-6574","authenticated-orcid":false,"given":"Helena M.","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-7425","authenticated-orcid":false,"given":"Mariana Macambira","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-399X","authenticated-orcid":false,"given":"Rim","family":"Abou Chakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-2267","authenticated-orcid":false,"given":"Louisa","family":"Liehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8949-6286","authenticated-orcid":false,"given":"Marina","family":"Rosanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Heng-Cheng Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-586X","authenticated-orcid":false,"given":"Jose Manuel","family":"Estrada-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104979_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104979_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104979_bib3","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104979_bib4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijgc.2026.104979_bib5","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104979_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104979_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104979_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","article-title":"Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"24","author":"Pignata","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104979_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.051","article-title":"LBA39 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd\/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced\/recurrent endometrial cancer","volume":"36","author":"Ginesta","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104979_bib10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104979_bib11","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104979_bib12","article-title":"PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis","volume":"19","author":"Carvalho Gouveia","year":"2025","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104979_bib13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104979_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"eLife"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104979_bib15","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"issue":"103538","key":"10.1016\/j.ijgc.2026.104979_bib16","article-title":"38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA\/rEC) in the overall and mismatch repair proficient (MMR\/MSS) populations and in histological and molecular subgroups: results from part 2 of the RUBY trial","volume":"9","author":"Mirza","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104979_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104774","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy","volume":"36","author":"Powell","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ijgc.2026.104979_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5512","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: longitudinal changes in circulating tumor DNA","volume":"43","author":"Westin","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijgc.2026.104979_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2026.01.777","article-title":"Biomarker heterogeneity and efficacy of durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E\/GOG-3041\/ENGOT-EN10 trial","volume":"206","author":"Westin","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104979_bib20","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104979_bib21","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/cancers12103026","article-title":"Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for platinum-sensitive ovarian cancer: systematic review and network meta-analysis","volume":"12","author":"Stemmer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104979_bib22","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ijgc.2026.104979_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5600","article-title":"Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA\/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"43","author":"Heitz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11_suppl","key":"10.1016\/j.ijgc.2026.104979_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/OP.2023.19.11_suppl.332","article-title":"Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA\/rEC) treated with dostarlimab (D) plus carboplatin\/paclitaxel (CP) compared with CP in the ENGOT-EN6\/GOG3031\/RUBY trial","volume":"19","author":"Mirza","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104979_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005484","volume":"35","author":"Valabrega","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104979_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/cancers18020258","article-title":"Quality of life measures in advanced endometrial cancer: a systematic review of reporting practices in phase III clinical trials","volume":"18","author":"Himpe","year":"2026","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104979_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/CJI.0000000000000603","article-title":"Immune-related adverse events among patients with endometrial cancer receiving pembrolizumab alone or with other treatments: a single-center real-world experience","volume":"49","author":"Boyles","year":"2026","journal-title":"J Immunother"},{"key":"10.1016\/j.ijgc.2026.104979_bib28","series-title":"Research. Approved Drug Prod Ther Equivalence Eval","year":"2026"},{"key":"10.1016\/j.ijgc.2026.104979_bib29","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) uterine neoplasms","author":"Abu-Rustum","year":"2025","journal-title":"Presented at: NCCN"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104979_bib30","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104979_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005883","article-title":"Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies","volume":"36","author":"Madariaga","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104979_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104979_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: a systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:31:48Z","timestamp":1794000708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26005104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26005104"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104979","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incremental risk of high-grade adverse events with immune checkpoint inhibitors with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in first-line treatment of advanced endometrial cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104979"}}